GeneDx warrant class removed from Nasdaq listing
GeneDx Holdings Corp. is having a class of its warrants removed from listing and registration on the Nasdaq Stock Market LLC under Section 12(b) of the Securities Exchange Act of 1934.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
25-NSE
Rhea-AI Filing Summary
GeneDx Holdings Corp. is having a class of its warrants removed from listing and registration on the Nasdaq Stock Market LLC under Section 12(b) of the Securities Exchange Act of 1934. Nasdaq certifies that it has complied with its own rules and the requirements of 17 CFR 240.12d2-2 to strike this warrant class from listing and/or withdraw its registration.
Key Figures
Commission File Number: 001-39482
Form approval expiration: March 31, 2018
Issuer telephone number: 888 729 1206
3 metrics
Commission File Number
001-39482
File number for the class of securities removed from listing
Form approval expiration
March 31, 2018
Expiration date shown in the header as “Expires: March 31, 2018”
Issuer telephone number
888 729 1206
Telephone number for GeneDx Holdings Corp. principal executive offices
Key Terms
Form 25, Section 12(b), withdraw registration, 17 CFR 240.12d2-2
4 terms
Form 25 regulatory
"FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION"
A Form 25 is an official filing with the U.S. Securities and Exchange Commission used to remove a company's stock or other security from a national exchange list. Investors should care because delisting often means less visibility, lower trading volume and wider price swings—similar to a product moving from a major supermarket to a small local market, which can make buying, selling and valuing the security more difficult.
Section 12(b) regulatory
"REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934"
Section 12(b) of the U.S. Securities Exchange Act requires securities listed on a national stock exchange to be registered with the U.S. Securities and Exchange Commission (SEC) and to follow regular public reporting and disclosure rules. For investors, a 12(b) listing generally means more routine financial updates, regulatory oversight and easier buying and selling—like a storefront that must display its inventory and prices, making it simpler to inspect and trade the product.
withdraw registration regulatory
"strike the class of securities from listing and/or withdraw registration on the Exchange"
17 CFR 240.12d2-2 regulatory
"Pursuant to 17 CFR 240.12d2-2(b) ... 17 CFR 240.12d-2(c)"
A U.S. Securities and Exchange Commission rule that describes the conditions and procedural steps for a security to be removed from public registration or reporting under the Securities Exchange Act of 1934. For investors, it matters because it explains when a company’s shares can stop being subject to regular disclosure and exchange listing rules — similar to knowing when a publicly tracked product will be discontinued and no longer send updates, which affects transparency and liquidity.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What action is Nasdaq taking regarding GeneDx Holdings Corp. (WGS) warrants?
Nasdaq is removing a class of GeneDx Holdings Corp. warrants from listing and registration under Section 12(b) of the Securities Exchange Act, as reflected in the filed Form 25.
Which securities of GeneDx Holdings Corp. (WGS) are affected by this Form 25?
The filing concerns a class of warrants of GeneDx Holdings Corp. It states “Warrant (Description of class of securities),” indicating that this specific warrant class is being removed from Nasdaq listing and registration.
Which exchange is delisting GeneDx Holdings Corp. (WGS) warrants?
The affected warrants are listed on the Nasdaq Stock Market LLC. Nasdaq certifies its compliance with 17 CFR 240.12d2-2 in striking this class of securities from listing and/or withdrawing registration.
Under which regulatory provisions are GeneDx (WGS) warrants being removed from listing?
The removal proceeds under 17 CFR 240.12d2-2(b) and 17 CFR 240.12d2-2(c), which govern exchange-initiated and issuer-complied procedures for striking a class of securities from listing and withdrawing registration under Section 12(b).
What is the Commission File Number for GeneDx Holdings Corp. (WGS) in this Form 25?
The filing lists Commission File Number 001-39482 for GeneDx Holdings Corp. This number identifies the registered class of securities being removed from listing and registration on Nasdaq.
Where is GeneDx Holdings Corp. (WGS) headquartered according to this document?
The principal executive offices are at 333 Ludlow Street, North Tower, 6th Floor, Stamford, Connecticut 06902, with a listed telephone number of 888 729 1206 for GeneDx Holdings Corp.
AI-generated analysis. How Rhea-AI works. Not financial advice.
